scholarly journals Cell therapy in bone healing disorders

2010 ◽  
Vol 2 (2) ◽  
pp. 20 ◽  
Author(s):  
Marcus Jäger ◽  
Philippe Hernigou ◽  
Christoph Zilkens ◽  
Monika Herten ◽  
Xinning Li ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Therapy ◽  
Bone Regeneration ◽  
Progenitor Cells ◽  
Clinical Application ◽  
Bone Healing ◽  
Bone Marrow Cells ◽  
Cell Based Therapy ◽  
Local Bone ◽  
Autologous Bone

In addition to osteosynthetic stabilizing techniques and autologous bone transplantations, so-called orthobiologics play an increasing role in the treatment of bone healing disorders. Besides the use of various growth factors, more and more new data suggest that cell-based therapies promote local bone regeneration. For ethical and biological reasons, clinical application of progenitor cells on the musculoskeletal system is limited to autologous, postpartum stem cells. Intraoperative one-step treatment with autologous progenitor cells, in particular, delivered promising results in preliminary clinical studies. This article provides an overview of the rationale for, and characteristics of the clinical application of cell-based therapy to treat osseous defects based on a review of existing literature and our own experience with more than 100 patients. Most clinical trials report successful bone regeneration after the application of mixed cell populations from bone marrow. The autologous application of human bone marrow cells which are not expanded ex vivo has medico-legal advantages. However, there is a lack of prospective randomized studies including controls for cell therapy for bone defects. Autologous bone marrow cell therapy seems to be a promising treatment option which may reduce the amount of bone grafting in future.

Development of cell therapy using autologous bone marrow cells for liver cirrhosis

2005 ◽  
Vol 38 (4) ◽  
pp. 197-202 ◽  
Author(s):  
Isao Sakaida ◽  
Shuji Terai ◽  
Hiroshi Nishina ◽  
Kiwamu Okita
Keyword(s):  
Bone Marrow ◽  
Liver Cirrhosis ◽  
Cell Therapy ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Autologous Bone ◽  
Marrow Cells

Tissue Engineering Strategies to Promote Bone Repair

2018 ◽  
Vol 941 ◽  
pp. 2495-2500 ◽  
Author(s):  
Anne Margaux Collignon ◽  
Gaël Y. Rochefort
Keyword(s):  
Tissue Engineering ◽  
Bone Regeneration ◽  
Bone Tissue ◽  
Bone Healing ◽  
Bone Repair ◽  
Population Aging ◽  
Local Bone ◽  
Bone Injury ◽  
Autologous Bone

Bone displays an amazing capacity for endogenous self-remodeling. However, compromised bone healing and recovering is on the ascent because of population aging, expanding rate of bone injury and the clinical requirement for the advancement of elective choices to autologous bone unions. Current strategies, including biomolecules, cell treatments, biomaterials and diverse combinations of these, are presently created to encourage the vascularization and the engraftment of the grafts, to reproduce at last a bone tissue with similar properties and attributes of the local bone. In this review, we look through the current techniques that are right now created, utilizing biomolecules, cells and biomaterials, to initiate, coordinate and potentiate bone regeneration and healing after damage and further talk about the natural procedures related with this repair.

scholarly journals Refractory Angina Cell Therapy (ReACT) Involving Autologous Bone Marrow Cells in Patients without Left Ventricular Dysfunction: A Possible Role for Monocytes

2009 ◽  
Vol 18 (12) ◽  
pp. 1299-1310 ◽  
Author(s):  
Nelson Americo Hossne ◽  
Adriana Luckow Invitti ◽  
Enio Buffolo ◽  
Silvia Azevedo ◽  
Jose Salvador Rodrigues de Oliveira ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Therapy ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Left Ventricular ◽  
Refractory Angina ◽  
Autologous Bone ◽  
Marrow Cells

A pilot study with autologous bone marrow-derived stem cell therapy in patients with severe peripheral arterial disorder

2008 ◽  
Vol 149 (12) ◽  
pp. 531-540 ◽  
Author(s):  
Zoltán Boda ◽  
Miklós Udvardy ◽  
Katalin Farkas ◽  
Judit Tóth ◽  
László Jámbor ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Pilot Study ◽  
Cell Therapy ◽  
Color Doppler ◽  
Autologous Bone Marrow ◽  
Thromboangiitis Obliterans ◽  
Arteriosclerosis Obliterans ◽  
Autologous Bone ◽  
Peripheral Arterial

Súlyos perifériás artériás érbetegségekben a gyógyszeres és/vagy érsebészeti beavatkozások kimerülését követően a tűrhetetlen fájdalom, kiterjedt végtagi fekélyek, gangraenák megszüntetésének egyetlen módja a végtag amputációja. Betegek és módszerek: A szerzők – hazánkban elsőként – 5 előrehaladott perifériás artériás érbetegben (1 arteriosclerosis obliterans és 4 thromboangiitis obliterans) autológ csontvelői eredetű őssejtterápiát végeztek. A csontvelői őssejteket (CD34+ sejtek) crista biopsia végzésével nyerték. Mágneses sejtszeparálással CD34+ sejtszuszpenziót állítottak elő. Meghatározták a CD34+, CD133+ és CD45± sejtek számát és arányát. Az őssejtszuszpenziót intramuscularis injekció formájában a beteg végtagba juttatták vissza. Betegenként 0,37–1,14 × 10 5 /kg őssejt visszaadására került sor. Betegeiket 12 hónapig követték. Vizsgálatok történtek a beavatkozás előtt és után (1, 3, 6, 9 és 12 hónappal). Klinikai vizsgálatok: nyugalmi fájdalom, dysbasiás távolság, ischaemiás fekélyek gyógyhajlama, boka-kar index. Laboratóriumi vizsgálatok: angiográfia (az őssejtterápia előtt és után 1 és 6 hónappal), duplex ultrahang- és lézer-Doppler-scan, transcutan oxigéntenzió mérése, az endothelfunkciók vizsgálata. Eredmények: A nyugalmi fájdalom mind az öt betegük esetében megszűnt. A dysbasiás távolság szignifikánsan nőtt (36/440 m). Három beteg végtagi ischaemiás fekélye begyógyult, egy beteg nagyméretű fekélye lényegesen kisebbé és felületesebbé vált, egy betegben a végtagi fekély nem változott. A kezelt oldalon a boka-kar index szignifikánsan nőtt (0,41/0,83) tizenkét hónappal az őssejtterápiát követően, s nem változott az ellenoldalon. Három betegben tapasztaltak számottevő változást angiográfiával az őssejtterápia után hat hónappal. Csak szerény javulást észleltek color-Doppler- és lézer-Doppler-vizsgálatokkal. Az őssejtterápia előtt és után 1, 6 és 12 hónappal a transcutan oxigéntenzió-értékek a lábháton 18,10/16,78/23,83/37,50 Hgmm-re, míg a lábszáron 36,66/31,25/45,00/37,30 Hgmm-re változtak. A makro- és mikrocirkulációs paraméterek nem mutattak javulást az őssejtterápiát követően 1 hónappal, azonban az őssejtterápia után 3, 6, 9 és 12 hónappal már mérhető javulást tapasztaltak. Szövődményt, mellékhatást nem észleltek. Következtetések: Klinikai eredményeik alapján az autológ csontvelői eredetű őssejtterápiát hatásosnak, tartósnak és biztonságosnak tartják előrehaladott perifériás artériás érbetegségben. Szükség van további klinikai tapasztalatgyűjtésre.

scholarly journals Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts

2021 ◽  
Vol 69 (1) ◽  
Author(s):  
Joanna Cwykiel ◽  
Arkadiusz Jundzill ◽  
Aleksandra Klimczak ◽  
Maria Madajka-Niemeyer ◽  
Maria Siemionow
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Fluorescent Microscopy ◽  
Study Endpoint ◽  
Solid Organ ◽  
Post Transplant ◽  
Group 4 ◽  
Cell Based Therapy ◽  
Group 3 ◽  
Group 1

AbstractThis study evaluated the efficacy of donor recipient chimeric cell (DRCC) therapy created by fusion of donor and recipient derived bone marrow cells (BMC) in chimerism and tolerance induction in a rat vascularized composite allograft (VCA) model. Twenty-four VCA (groin flaps) from MHC-mismatched ACI (RT1a) donors were transplanted to Lewis (RT1l) recipients. Rats were randomly divided into (n = 6/group): Group 1—untreated controls, Groups 2—7-day immunosuppression controls, Group 3—DRCC, and Group 4—DRCC with 7-day anti-αβTCR monoclonal antibody and cyclosporine A protocol. DRCC created by polyethylene glycol-mediated fusion of ACI and Lewis BMC were cultured and transplanted (2–4 × 106) to VCA recipients via intraosseous delivery route. Flow cytometry assessed peripheral blood chimerism while fluorescent microscopy and PCR tested the presence of DRCC in the recipient’s blood, bone marrow (BM), and lymphoid organs at the study endpoint (VCA rejection). No complications were observed after DRCC intraosseous delivery. Group 4 presented the longest average VCA survival (79.3 ± 30.9 days) followed by Group 2 (53.3 ± 13.6 days), Group 3 (18 ± 7.5 days), and Group 1 (8.5 ± 1 days). The highest chimerism level was detected in Group 4 (57.9 ± 6.2%) at day 7 post-transplant. The chimerism declined at day 21 post-transplant and remained at 10% level during the entire follow-up period. Single dose of DRCC therapy induced long-term multilineage chimerism and extended VCA survival. DRCC introduces a novel concept of customized donor-recipient cell-based therapy supporting solid organ and VCA transplants.

Abstract 295: The Stem Cell Therapy to Prevent Expansion of Abdominal Aortic Aneurysm (STOP-AAA) Trial: Rationale and Design

2014 ◽  
Vol 34 (suppl_1) ◽  
Author(s):  
Michael P Murphy ◽  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Abdominal Aortic Aneurysm ◽  
Aortic Aneurysm ◽  
Cell Therapy ◽  
Autologous Bone Marrow ◽  
Research Network ◽  
Stem Cell Population ◽  
Abdominal Aortic ◽  
Autologous Bone

Background: Abdominal aortic aneurysm (AAA) is the 13 th leading cause of death in the United States. The only options for treatment at present for AAA are open surgical and endovascular repair, both of which are associated with significant morbidity, mortality, and expense.Thus AAA represents an unmet medical need. AAA pathogenesis is a multifactorial inflammatory process characterized by activation of T-cells,macrophages and neutrophils resulting in degradation of the aortic wall. Mesenchymal stromal cells (MSCs) suppress T-cell and macrophage activation, inhibit matrix metalloproteinases and have been shown to decrease aneurysm expansion in murine models. Methods: The STOP-AAA trial, from the NHLBI funded Cardiovascular Cell Therapy Research Network, is a randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of autologous bone marrow derived MSCs in suppressing expansion of small AAA (35-50mm).Forty patients will be randomized in a 1:1 fashion to receive systemic administration of placebo or 3 doses of 2x10 6 MSC/kg. at baseline, 24, and 52 weeks. The primary endpoint will be change in AAA diameter at 18 months as measured by a single blinded observer using contrast enhanced helical computed tomographic angiography (CTA).The secondary endpoints include time to elective repair, incidence of AAA related deaths and rupture,change in aortic mural inflammation at 18 months as quantified by F18-fluorodeoxyglucose (FDG) uptake with integrated positron emission tomography and computed tomography (PET/CT), changes in circulating mRNA, microRNA, and inflammatory cell profiles, changes in serum cytokine levels, and major adverse cardiac events. Conclusion: The STOP-AAA will be the first in man study to assess the efficacy of autologous bone marrow derived MSCs to suppress AAA expansion. Furthermore the data collected from this novel trial will provide unique mechanistic insights in the immunomodulatory properties of this stem cell population.

Fracture induced mobilization and incorporation of bone marrow-derived endothelial progenitor cells for bone healing

2008 ◽  
Vol 215 (1) ◽  
pp. 234-242 ◽  
Author(s):  
Tomoyuki Matsumoto ◽  
Yutaka Mifune ◽  
Atsuhiko Kawamoto ◽  
Ryosuke Kuroda ◽  
Taro Shoji ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Bone Healing ◽  
Endothelial Progenitor

scholarly journals Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration

Gene Therapy ◽  
2003 ◽  
Vol 10 (24) ◽  
pp. 2013-2019 ◽  
Author(s):  
S C-N Chang ◽  
H L Chuang ◽  
Y R Chen ◽  
J K Chen ◽  
H-Y Chung ◽  
...  
Keyword(s):  
Stem Cells ◽  
Gene Therapy ◽  
Bone Marrow ◽  
Bone Regeneration ◽  
Ex Vivo ◽  
Autologous Bone Marrow ◽  
Ex Vivo Gene Therapy ◽  
Autologous Bone ◽  
Stromal Stem Cells
Sign in / Sign up

Export Citation Format

Share Document